Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Theratechnologies Inc: Premium Company Profile

Published by: Datamonitor

Published: Apr. 22, 2008 - 45 Pages


Table of Contents


Overview
Catalyst
Summary
Table of Contents
Table of figures
Table of tables
Company Structure
Company Overview and Key Facts
Business Description
Landmark Products and Services
ExoPEP and LAP technologies
History
M&A History
Pharma-G
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products & Services
Pipeline Products
In-house Pipeline
TH9507 (tesamorelin)
ThGRF
THG213.29
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Key Clients
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Acquisition of Pharma-G
Weaknesses
Discontinuation of ThGRF for other indications
Weak product pipeline
Opportunities
TH9507 being developed for HIV-associated lipodystrophy
Strategic alternatives
Threats
Lengthy and expensive regulatory process
Value Chain Analysis
Overview
Discovery and Product Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Yves Rosconi
Luc Tanguay
Paul Pommier
A Jean de Grandpré
Gilles Cloutier
Robert G Goyer
Gérald A Lacoste
Bernard Reculeau
Jean-Denis Talon
Pierre Caudrelier
Marie-Noël Colussi
Chantal Desrochers
Jocelyn Lafond
Christian Marsolais
Martine Ortega
Pierre Perazzelli
Krishna Peri
Andrea Gilpin
Mark Reimer
Financial and Operational Overview
Financial and Operational Overview
APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer
List of Tables
Table 1: Theratechnologies - Key Facts
Table 2: Theratechnologies - Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 3: Theratechnologies - Key Events Impacting Share Price Performance
Table 4: Theratechnologies - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 5: Theratechnologies - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 6: Theratechnologies - Balance Sheet, 2002-2006 ($ Mn)
Table 7: Theratechnologies - Cash Flow, 2002-2006 ($ Mn)
Table 8: Theratechnologies - Revenue Breakdown by Division, 2002-2006 ($ Mn)
Table 9: Theratechnologies - In-house Pipeline Products
Table 10: Theratechnologies - Forecast Sales, 2006-2010 ($ Mn)
Table 11: Theratechnologies - Key Competitors
Table 12: Theratechnologies - Key Suppliers
Table 13: Theratechnologies - Key Clients
Table 14: Theratechnologies - SWOT Analysis Summary
Table 15: Theratechnologies - Value Chain Analysis
Table 16: Theratechnologies - Scorecard
Table 17: Theratechnologies - Key Employees
Table 18: Theratechnologies - Financial and Operational Overview
List of Figures
Figure 1: Theratechnologies - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: Theratechnologies - Key Strategic Revenues, 2006-2010 ($ Mn)


Abstract

Introduction

Theratechnologies is a Canadian biopharmaceutical company developing therapeutic peptides for endocrine and metabolic disorders. The company has developed its product pipeline utilizing two technologies ExoPep and LAP (Long Acting Peptide).

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company’s pipeline products include: TH9507 being developed for HIV-Associated Lipodystrophy (Phase III); ThGRF being developed for growth hormone deficiency (Phase I), and cystic fibrosis (Phase I); and THG213.29 being developed for renal disease (preclinical). The company recognizes revenues in the form of royalties, and interest on investments from other pharmaceutical/biotechnology companies like ALZA pursuant to its co-development agreements. The company’s total revenues declined at a CAGR of 33.8% from $7.6 million to $1.5 million during the period 2002-2006. This represents an absolute decline of -$6.1 million for the period of analysis. The company derived its revenues from royalties, and interest on investments.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .

Please note: This is delivered as a Zip file.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008